IN8bio Shares Are Trading Higher After the Company Announced New Preclinical Data From Its Non-signaling Gamma-delta T Cell Based Chimeric Antigen Receptor-T Cell Platform
In8bio公佈了其基於非信號 gamma-Delta T 細胞的嵌合抗原受體-T 細胞平台的新臨床前數據後,該公司股價走高
IN8bio Shares Are Trading Higher After the Company Announced New Preclinical Data From Its Non-signaling Gamma-delta T Cell Based Chimeric Antigen Receptor-T Cell Platform
In8bio公佈了其基於非信號 gamma-Delta T 細胞的嵌合抗原受體-T 細胞平台的新臨床前數據後,該公司股價走高
使用瀏覽器的分享功能,分享給你的好友吧